Panel Discussion: State of Play of Retinal Vascular Drug Development
Time: 9:00 am
day: Conference Day 1
Details:
- What are the unique challenges of developing safe and efficacious drugs for Wet AMD vs DR vs DME? How are these different from the challenges when developing therapeutics for Dry AMD and GA?
- What do the current clinical pipelines look like for Wet AMD vs DR vs DME vs RVO?
- What does the future of the retinal vascular drug development field look like?
